利妥昔单抗联合CHOP方案治疗B细胞非霍奇金淋巴瘤的疗效分析

目的：探讨利妥昔单抗联合CHOP方案治疗B细胞型非霍奇金淋巴瘤（NHL）的临床效果和不良反应。方法选择96例CD20阳性的B细胞NHL患者分为研究组49例和对照组47例，研究组采用利妥昔单抗与CHOP方案联合治疗方案，对照组只采用CHOP化疗方案。应用4个疗程后评价两组疗效及不良反应。结果研究组治疗有效率为90.0%，高于对照组的72.3%，差异有统计学意义（P﹤0.05）。而且两组的白细胞下降、脱发、恶心呕吐、便秘、血小板减少、贫血、肺部感染等不良反应比较，差异无统计学意义（P﹥0.05）。研究组1年、3年、5年无进展生存率（PFS）分别为81.6%、61.2%、26.5%，生存率分别为89.8%、65.3%、30.6%，均高于对照组，差异均有统计学意义（P﹤0.05）。结论采用利妥昔单抗与CHOP联合方案治疗B细胞非霍奇金淋巴瘤，可以提高临床疗效和远期生存率，且不因联合化疗而增加不良反应。

Efficacy of rituximab combined with CHOP regimen in the treatment of B cell non-Hodgkin's lymphoma

Objective To investigate the clinical effect and adverse reaction of rituximab combined with CHOP regi-men in the treatment of diffuse large B cell non-Hodgkin’s lymphoma (NHL). Method 96 cases of CD20 positive B cell NHL patients were enrolled in the study and were randomized into study group or control group, the study group was treated with combined therapy of rituximab+CHOP, while the control group was administered with CHOP chemotherapy alone. The efficacy and adverse reactions were evaluated after 4 cycles of treatment. Result The response rate was 90.0%in study group, higher than that of the control group at 72.3%(P<0.05). The incidences of leukocytopenia, alope-cia, nausea and vomiting, constipation, thrombocytopenia, anemia, pulmonary infection and other adverse reactions were similar between the two group (P>0.05). The 1-, 3-, and 5-year progression free survival (PFS) in the study group was 81.6%, 61.2%and 26.5%, and the overall survival rate (OS) was 89.8%, 65.3%, 30.6%, respectively, all were higher than those in the control group, with significant difference observed (P<0.05). Conclusion Rituximab combined with CHOP regimen may improve clinical efficacy and long-term survival in the treatment of B cell non-Hodgkin's lymphoma, with no increased adverse reactions induced by combined chemotherapy.